The immune response of splenic lymphocytes after cimicifugoside treatment in vitro and pretreatment in vivo.
Pretreatment of mouse splenocytes with Shigella lipopolysaccharide and concanavalin A followed by 50 ng/ml of cimicifugoside resulted in a 69% and 31% inhibition of blastogenesis compared to controls. The plaque forming colony assay using sheep erythrocytes (SRBC) showed a decreased number of plaque forming colonies after exposure of the splenic cells to 1 microgram/ml of cimicifugoside. Cimicifugoside, 0.1 mg/mouse i.p. suppressed the anti-SRBC response in the plaque forming assay. The major inhibition of the antibody response occurred when cimicifugoside was administered 1 day before the primary immunization with SRBC. The delayed type hypersensitivity to picryl chloride was suppressed after i.v. administration of cimicifugoside, 1.0-2.0 mg/mouse. The immunosuppressive activity of cimicifugoside is preferentially directed toward B-cell function with larger doses being required for suppression of T-cell function.
D000818:Animals; D004912:Erythrocytes / Q000276:immunology; D005260:Female; D006968:Hypersensitivity, Delayed; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007810:Lanosterol / Q000031:analogs & derivatives* / Q000494:pharmacology; D007930:Leucine / Q000378:metabolism; D008213:Lymphocyte Activation / Q000187:drug effects; D008214:Lymphocytes / Q000187:drug effects* / Q000276:immunology; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D008934:Mitogens / Q000494:pharmacology; D013154:Spleen / Q000276:immunology; D013936:Thymidine / Q000378:metabolism; D014315:Triterpenes / Q000494:pharmacology*
D007166:Immunosuppressive Agents; D008934:Mitogens; D014315:Triterpenes; D007810:Lanosterol; C031436:cimicifugoside; D007930:Leucine; D013936:Thymidine